T-cell Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for T-cell Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-11-05Clinical Trial Update: BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients [Phase 3]
This is a Phase 3 clinical trial comparing Busulfan-Cyclophosphamide (BuCy) versus Total Body Irradiation-Cyclophosphamide (TBICy) condition…
-
CLINICAL_TRIALS research · 2024-10-09Clinical Trial Update: Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL [EARLY_Phase 1]
The entry reports an early-phase 1 clinical trial evaluating CD5-targeted CAR-T cells for relapsed/refractory CD5-positive T-cell acute lymp…
-
CLINICAL_TRIALS research · 2024-09-24Clinical Trial Update: BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma. [Phase 2]
A Phase 2 clinical trial evaluating BCL-2 inhibitors in combination with the HyperCVAD regimen for newly diagnosed T-cell lymphoblastic leuk…
-
FDA approval · 2024-09-13FDA Approved: NELARABINE — Original Application (Novadoz Pharmaceuticals LLC)
The FDA approved an original-application abbreviated new drug application for nelarabine from Novadoz Pharmaceuticals LLC, enabling the mark…
-
FDA approval · 2024-09-05FDA Approved: NELARABINE — Original Application (XGen Pharmaceuticals DJB, Inc.)
FDA approved the original application for nelarabine as a generic drug, with XGen Pharmaceuticals DJB, Inc. listed as the manufacturer.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-08-01FDA Approved: NELARABINE — Original Application (Alembic Pharmaceuticals Limited)
The FDA approved Alembic Pharmaceuticals Limited's Nelarabine Original Application (ANDA 218554), granting approval for a generic Nelarabine…
-
CLINICAL_TRIALS trial_result · 2024-07-29Clinical Trial Update: MRD Detection by NGS in Pediatric T-ALL
This clinical trial update describes using next-generation sequencing to detect minimal residual disease in pediatric T-cell acute lymphobla…
-
CLINICAL_TRIALS withdrawal · 2024-05-17Clinical Trial Update: Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) [Phase 2]
This clinical trial update notes withdrawal of a Phase 2 study evaluating adding targeted drugs to standard chemotherapy for adults with new…
-
CLINICAL_TRIALS research · 2024-04-26Clinical Trial Update: Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients [Phase 3]
A Phase 3 trial compares haplo-cord hematopoietic stem cell transplantation with haploidentical HCT in patients with T-cell acute lymphoblas…
-
FDA approval · 2024-01-03FDA Approved: NELARABINE — Original Application (Sagent Pharmaceuticals)
FDA approved Nelarabine under an Original Application from Sagent Pharmaceuticals. It is indicated for T-cell acute lymphoblastic leukemia a…
-
CLINICAL_TRIALS trial_result · 2023-03-20Clinical Trial Update: Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath [Phase 2]
Phase 2 trial update investigating MabCampath for relapsed T-cell acute lymphoblastic leukemia or T-lymphoblastic lymphoma.
-
FDA approval · 2023-03-03FDA Approved: NELARABINE — Original Application (Shorla Oncology Inc.)
The FDA approved a generic Nelarabine (Shorla Oncology Inc.) under an Original Abbreviated New Drug Application, confirming bioequivalence t…
-
FDA approval · 2023-01-10FDA Approved: NELARABINE — Original Application (Meitheal Pharmaceuticals Inc)
FDA approves Meitheal Pharmaceuticals' nelarabine original application (ANDA216038) for a generic formulation of nelarabine.
-
FDA approval · 2022-12-22FDA Approved: NELARABINE — Original Application (Dr. Reddy's Laboratories, Inc.)
FDA approves Dr. Reddy's Nelarabine as a generic under an Original Application for use in treating T-cell acute lymphoblastic leukemia and T…
-
CLINICAL_TRIALS trial_result · 2022-10-28Clinical Trial Update: Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL [Phase 2]
Phase 2 clinical trial evaluating a Modified TBF conditioning regimen before allogeneic stem cell transplant in T-ALL/LBL.
-
CLINICAL_TRIALS trial_result · 2022-08-18Clinical Trial Update: 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL) [Phase 2]
Phase 2 clinical trial update for 506U78 in relapsed or refractory acute lymphoblastic leukemia (T-ALL) and T-NHL (lymphoblastic).
-
CLINICAL_TRIALS trial_result · 2022-05-24Clinical Trial Update: Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial evaluating sapanisertib in adults with relapsed or refractory acute lymphoblastic leukemia; results were posted in Ma…
-
CLINICAL_TRIALS trial_result · 2022-02-23Clinical Trial Update: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma [Phase 3]
A Phase 3 clinical trial evaluating combination chemotherapy with or without bortezomib in younger patients with newly diagnosed T-cell acut…
-
CLINICAL_TRIALS trial_result · 2022-02-23Clinical Trial Update: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma [Phase 3]
A Phase 3 trial evaluating whether adding bortezomib to combination chemotherapy improves outcomes in younger patients with newly diagnosed …
-
FDA approval · 2021-11-17FDA Approved: NELARABINE — Original Application (Zydus Lifesciences Limited)
FDA approved the original application for Nelarabine from Zydus Lifesciences Limited, enabling generic access for treating T-cell acute lymp…
-
CLINICAL_TRIALS trial_result · 2020-10-01Clinical Trial Update: Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL [Phase 1, Phase 2]
Phase 1/2 trial evaluating nelarabine combined with etoposide and cyclophosphamide in relapsed T-cell ALL and T-cell lymphoblastic lymphoma;…
-
CLINICAL_TRIALS trial_result · 2020-01-18Clinical Trial Update: Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia [Phase 2]
Phase 2 trial of isatuximab in T-cell precursor acute leukemia/lymphoblastic lymphoma-leukemia was terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2019-10-21Clinical Trial Update: Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old) [Phase 2]
Phase 2 multicenter study evaluating risk-adapted treatment for T-lineage/ T-cell adult acute lymphoblastic leukemia in young adults (18-59)…
-
CLINICAL_TRIALS trial_result · 2019-09-19Clinical Trial Update: Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies [Phase 1, Phase 2]
A multi-CAR T therapy targeting CD7 is being studied in Phase 1/Phase 2 for CD7-positive malignancies including T-cell acute lymphoblastic l…
-
FDA approval · 2019-08-02FDA Approved: ARRANON — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for ARRANON (nelarabine) submitted by Sandoz Inc.